Home › Cases › PE in Pregnancy
Pulmonary Embolism
PE in Pregnancy
6 questions
Question 1 · Diagnosis challenge
Correct answer: It is raised but does not diagnose PE; urgent assessment and appropriate imaging are needed
Why
Pregnancy often raises D-dimer; this raised result neither confirms nor excludes PE. RCOG37b advises against D-dimer testing and standard Wells assessment in pregnancy. Start treatment-dose LMWH unless contraindicated and arrange urgent investigation with senior and obstetric input: ECG, CXR, then CTPA or V/Q. If there are DVT symptoms, compression ultrasound may confirm VTE without chest imaging.
Key point
Pregnancy: don't rely on D-dimer or Wells. Treatment-dose LMWH unless contraindicated, then urgent imaging.
Question 2 · Imaging choice
Correct answer: VQ scan preferred first if CXR normal — less radiation to breast tissue. CTPA if CXR abnormal or VQ unavailable
Why
With a normal CXR, V/Q scanning often gives less maternal breast radiation. CTPA is preferred if CXR is abnormal or V/Q unavailable; fetal exposure may be similar or lower with CTPA. Absolute radiation risks are small: do not delay indicated imaging.
Key point
PE in pregnancy: VQ scan preferred (less breast radiation). CTPA if CXR abnormal or VQ unavailable.
Question 3 · Anticoagulation in pregnancy
Correct answer: LMWH (low molecular weight heparin) — weight-adjusted dose throughout pregnancy
Why
Anticoagulation in pregnancy: LMWH (e.g. enoxaparin, dalteparin) is the drug of choice. Does not cross the placenta. Avoid DOACs in pregnancy: fetal safety is insufficiently established. Warfarin crosses the placenta and causes warfarin embryopathy in 1st trimester.
Key point
Pregnancy PE: LMWH first-line. Avoid DOACs and warfarin for antenatal VTE; UFH may be used with specialists if unstable.
Question 4 · Dose adjustment in pregnancy
Correct answer: Use booking/early-pregnancy weight; anti-Xa monitoring only for selected higher-risk patients
Why
Dose therapeutic LMWH using booking/early-pregnancy weight. Routine anti-Xa monitoring is not recommended. Seek specialist monitoring for renal impairment, extremes of weight or recurrent VTE. Pregnancy changes clearance, but this does not justify routine testing in every patient.
Key point
Booking/early-pregnancy weight for LMWH; selective anti-Xa monitoring.
Question 5 · Peripartum management
Correct answer: Agree a delivery plan: withhold therapeutic LMWH at least 24h before planned delivery; restart after bleeding and neuraxial checks
Why
- Therapeutic LMWH: stop at least 24h before planned delivery or neuraxial anaesthesia; omit further doses if labour starts.
- UFH is an option near term for selected high-risk patients because it is short-acting and reversible with protamine; no routine 36-week switch.
- Obstetric, anaesthetic and haematology teams must agree restart timing after haemostasis and neuraxial checks; do not prescribe a universal 4–6h therapeutic restart.
Key point
Plan delivery with the team. Therapeutic LMWH: at least 24h interval; restart only after bleeding and neuraxial checks.
Question 6 · Post-partum duration
Correct answer: At least 3 months from PE AND minimum 6 weeks post-partum — whichever is longer
Why
Pregnancy-associated PE: anticoagulate minimum 3 months from PE AND minimum 6 weeks post-partum (puerperal period has highest thrombotic risk). During breastfeeding, LMWH or warfarin are established choices. SPS permits rivaroxaban or dabigatran when indicated in healthy full-term infants, with infant monitoring; avoid apixaban/edoxaban. Reassess at 3 months.
Key point
At least 3 months total AND 6 weeks postpartum. Check the specific anticoagulant before switching during breastfeeding.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.